FAH and hepatocellular carcinoma: Recently, using Fah−/− mouse model of HCC, the authors demonstrated that Palbociclib-induced hepatocellular senescence effectively restricted the occurrence of HCC following Palbociclib administration in the early-phase, but surprisingly enhanced the development of HCC in the late period of drug treatment.